argenx CIDP joins the party
argenx meets and exceeds our expectations with a broad label approval for CIDP, the 2nd approved indication in the US, which unlocks Vyvgart regardless of prior therapies. Based on updated patient population estimates and a premium $ 450k net pricing, we upgrade our peak sales estimate from $ 3.05bn to $ 3.76bn and increase our TP to € 460 (previously € 420 while we reiterate our Buy rating.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.